期刊
ACS INFECTIOUS DISEASES
卷 1, 期 5, 页码 186-197出版社
AMER CHEMICAL SOC
DOI: 10.1021/id5000426
关键词
Ebola virus; viral hemorrhagic fever; innate immunity; adaptive immunity; immunoevasion; antivirals; Ebola vaccines; Ebola therapeutics
资金
- NIAID NIH HHS [U19 AI109945] Funding Source: Medline
The filoviruses, Ebola virus (EBOV) and Marburg virus (MARV), are among the deadliest viruses that cause disease in humans, with reported case fatality rates of up to 90% in some outbreaks. The high virulence of EBOV and MARV is largely attributed to the ability of these viruses to interfere with the host immune response. Currently, there are no approved vaccines or postexposure therapeutics, and treatment options for patients infected with EBOV are limited to supportive care. In this review, we discuss mechanisms of EBOV pathogenesis and its ability to subvert host immunity as well as several vaccines and therapeutics with respect to their evaluation in small animal models, nonhuman primates, and human clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据